Future Cancer Diagnosis: Accelerating the Detection of Pancreatic and Ovarian Cancer - What is the New Blood Test Trial in the UK?

To Not Overlook "Abdominal Bloating"—A Blood Test to Detect Multiple Cancers, a Large-Scale Trial for 20,000 People in the UK

Your stomach feels bloated. The pain and discomfort persist. But you're unsure if it's serious enough to visit a hospital.

These symptoms can be difficult for patients to describe and challenging for doctors to diagnose. What seems like a common ailment might actually be the gateway to a condition that requires thorough investigation.

Could a blood test assist in making this determination? A new large-scale trial is set to begin in the UK.

According to the BBC, a blood test that screens for signs of multiple cancers simultaneously will be offered on a trial basis at about 200 general practitioner clinics in England. The trial targets over 20,000 patients aged 45 and older who experience symptoms like abdominal pain or persistent bloating. This research, called "STRIDE-RCT," is led by the University of Birmingham.

It's important to note that the goal is not to complete the diagnosis with just a blood test. The aim is to quickly identify patients with ambiguous symptoms who need further detailed examinations.

The Target This Time is "Symptomatic Individuals"

When you hear "detecting multiple cancers through blood," you might imagine a system that checks for all types of cancer in one go, in addition to routine health check blood tests.

However, understanding the trial in this way would misinterpret its purpose.

STRIDE-RCT targets patients who already have abdominal discomfort and visit their general practitioner. In the UK, GPs serve as the first point of contact for health issues and refer patients to specialized care if necessary.

The trial will investigate whether this new blood test can be a useful tool in these consultations.

The role of tests differs between widespread screening for asymptomatic individuals and diagnosing the cause in symptomatic individuals. Understanding this distinction makes the news easier to grasp.

The expectation for the new test is that it will provide more clues to connect patients' complaints to appropriate detailed examinations.

Using Proteins and DNA Fragments in Blood as Clues

According to the BBC, the test examines proteins and DNA fragments in the blood to look for signals that might indicate the presence of cancer.

Patients will provide one or two vials of blood at the clinic, in addition to their usual tests. Researchers will analyze these samples to determine if there are signs of cancer and, if so, which part of the body they might originate from.

The cancers targeted in the trial include those of the colon, small intestine, stomach, esophagus, pancreas, liver, bile duct, gallbladder, ovaries, endometrium, kidneys, bladder, and prostate.

However, being included as a target does not guarantee that all cancers will be detected with the same accuracy. The current announcement does not specify how well early-stage cancers can be detected.

The University of Birmingham's research information also registers STRIDE-RCT as a trial for a blood-based multi-cancer detection test. It is a study to gather evidence sufficient for widespread use in general practice, not an announcement of the full implementation of an established test.

Why "Ambiguous Symptoms" Matter

Abdominal symptoms do not always directly lead to a diagnosis.

As explained by Professor Peter Johnson, NHS England's cancer care lead, in a BBC article, abdominal cancers can be easily confused with other relatively mild illnesses, making early detection difficult.

For patients, the uncertainty of persistent symptoms without a clear cause can be anxiety-inducing. Meanwhile, healthcare providers must decide which patients should be prioritized for which tests.

This is where a blood test might be useful.

If a clue about which area needs further investigation can be obtained in situations where diagnosis is difficult with just interviews, examinations, and usual tests, it becomes easier to choose the next test.

However, this is a potential goal of the trial. Whether it can actually shorten the time to diagnosis, and how much it might lead to missed diagnoses or unnecessary tests, needs to be evaluated based on the results.

"Positive = Cancer" and "Negative = Reassurance" Are Not the Same

The most important aspect of understanding this test is how to interpret the results.

A positive result means a signal indicating the possibility of cancer was found. It does not confirm cancer, and additional tests are required for diagnosis.

Conversely, a negative result does not guarantee the absence of cancer.

The U.S. National Cancer Institute also explains that for multi-cancer detection tests, a positive result requires confirmatory tests, and even with a negative result, cancer may be diagnosed later.

The issue here is "false positives," where cancer is not present but the test is positive, and "false negatives," where cancer is present but the test is negative.

With false positives, patients undergo additional tests while carrying anxiety. With false negatives, there is a risk of delaying response to ongoing symptoms due to over-reliance on the result.

The minimal burden of blood sampling can be an advantage. However, the impact of the test does not end at the moment of blood collection. It is necessary to consider the explanation of results, subsequent tests, and the response until a diagnosis is made.

The Distance Between Expectations and Proof Shown by the Galleri Trial

Research on detecting multiple cancers through blood is not new.

In the UK, a separate large-scale trial called "NHS-Galleri" has been underway. This research examines whether adding a blood test to existing screenings can detect cancer at an earlier stage.

The results published in 2026 showed that the primary goal of reducing the number of diagnoses of advanced cancers at stages 3 and 4 combined was not achieved.

However, the trial also reported fewer diagnoses of the most advanced stage 4 cancers in the latter part of the screenings. The research team continues additional follow-ups and analyses.

This outcome cannot be simply labeled as a success or a failure of the entire blood test technology.

However, the fact that the primary pre-set goals were not achieved should not be replaced solely by favorable secondary outcomes. Detecting cancer signals and improving patient outcomes need to be verified separately.

Moreover, the Galleri trial and STRIDE-RCT target different patients and use the test in different contexts. The results of the former cannot directly predict the success of the latter.

On Social Media, "Wanting Early Detection" and "Being Missed Despite a Negative" Intersect

There are not enough social media posts directly responding to the STRIDE-RCT announcement itself within the range confirmed. Therefore, reactions from users on the public forum Reddit regarding related multi-cancer blood tests are introduced. Note that these are personal anecdotes and not direct responses to the current trial.

One user posted that after no cancer signal was detected in a blood test, further examinations prompted by a mammogram the following month led to an early-stage breast cancer diagnosis.

The individual had hoped that the blood test would detect cancer before it became visible in imaging. The post received reactions celebrating the early detection and comments cautioning against replacing traditional screenings with blood tests.

This anecdote is not independently verified through medical records, nor is it research data indicating test accuracy. Nonetheless, it provides material for considering the gap between user expectations for new tests and the meaning of the results.

"No signal found" is not the same as "no cancer."

While individual social media posts cannot determine overall public opinion, it is clear that, in addition to technology, clear communication of results is necessary for the test's widespread adoption.

What to Keep in Mind When Reading This News in Japan

This announcement concerns a trial conducted within the UK's healthcare system. It should not be interpreted as an indication that the same test can immediately be accessed in Japan or that it will replace existing cancer screenings.

Japan's National Cancer Center "Cancer Information Service" advises that if there are concerning symptoms, one should visit a medical institution without waiting for a screening.

If there are symptoms such as stomach pain, discomfort, blood in the stool, abdominal pain, or changes in bowel movements, it is essential to consult about the symptoms and undergo appropriate tests for diagnosis.

Moreover, even if no abnormalities are pointed out in a screening, if concerning symptoms appear afterward, there is no need to wait until the next screening.

The fact that the trial targets those aged 45 and older does not mean that symptoms in those under 45 should be taken lightly. The conditions for participating in the research and whether an individual should seek medical attention are separate matters.

What Really Matters is What Happens "After" the Blood Draw

The concept of examining multiple cancers from a small amount of blood is highly appealing. Especially for cancers that are difficult to detect, the significance of having more clues that lead to diagnosis is substantial.

However, the value of a new test is not determined solely by how many types of cancer it targets.

Can necessary patients be quickly connected to appropriate tests? Will those with ongoing symptoms be overlooked despite a negative result? Can those who test positive be diagnosed without excessive anxiety or unnecessary burden?

The value of the technology becomes clear only when the results of the blood draw are connected to meaningful medical care for the patient.

STRIDE-RCT is an attempt to verify that potential in real-world clinical settings. While we watch with anticipation, it's important to consult about any current concerning symptoms without waiting for future tests. Both aspects should be valued.

Sources and References

1. BBC News:
   Details on STRIDE-RCT participants, participating clinics, blood collection methods, detection targets, and expert explanations.
   https://www.bbc.com/news/articles/cm9qz93ew22no

2. University of Birmingham: STRIDE-RCT Research Registration Information
   Confirmation of the trial's official name, research structure, and funding by NIHR.
   https://research.birmingham.ac.uk/en/projects/stride-rct-a-cluster-platform-trial-of-blood-based-multi-cancer-d/University of Birmingham

3. NHS-Galleri Trial Official Site: Publication of Initial Research Results
   Explanation of the failure to achieve the primary goal and the continuation of follow-up and analysis.
   https://www.nhs-galleri.org/trial-updates/first-full-nhs-galleri-results-published-in-leading-journalsnhs-galleri.org

4. NHS-Galleri Trial Official Site: Results by Cancer Stage and Future Evaluation
   Reference to distinguish between the primary evaluation of stages 3 and 4 combined and the reduction in stage 4 observed in later screenings.
   https://www.nhs-galleri.org/trial-updates/nhs-galleri-trial-reports-fewer-diagnoses-of-the-most-advanced-cancersnhs-galleri.org

5. U.S. National Cancer Institute: Q&A on Multi-Cancer Detection Tests
   Confirmation of the meaning of positive and negative results, the necessity of additional tests, and the importance of continuing existing screenings.
   https://prevention.cancer.gov/sites/default/files/2024-12/mcd-questions-answers.pdfprevention.cancer.gov

6. Reddit: User Posts and Comments on Related Blood Tests
   Self-reported case of being diagnosed with breast cancer after a negative result and the reactions to it. Not a direct response to STRIDE-RCT or medically verified material.
   https://www.reddit.com/r/Function_Health/comments/1ungkor/anyone_know_the_basis_for_this_cancer_claim/reddit.com

7. National Cancer Center "Cancer Information Service": About Cancer Screenings
   Confirmation that if there are symptoms, one should not wait for a screening to seek medical attention, and that consultation is necessary even if no abnormalities are found in screenings.
   https://ganjoho.jp/public/pre_scr/screening/about_scr01.html